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Blister fluids from a va riety of bull ous diso rders were ex-
amined fo r the presence of human collagenase inhibitor. A 
pro tein immunologically identical to th e collagenase in-
hibitor produced by human skin fibroblas ts w as found in 
high concentrations w ithin bullae of diverse etiologies . Levels 
of collagenase inhibitor in blister fluids ranged fro m 0.9-12.5 
,ug/ml , ave tagin g 4.9 ,ug/ ml. T he m ean values were 3- to 
4- fo ld grea ter than those present in the sera of correspond-
ing patients and exceeded plas m.a levels by 6- to 8-fold . 
T he tim e course of collagenase inhibitor accumul ation in 
C olli\genases occup y a crucial pos iti on in th e m odu-b tion of connecti ve ti ssue turnover, since they ca t-alyze the initial and also the ra te-limiting step o f coll agen degradati on [1-3J. U sin g hum an skin fi -bro blast coll agenase as a proto type of m ammali an 
interstitial coJJagenases, considerable kn owledge has been accu-
m ulated regardin g the b iosynthes is [4], zy mogen ac ti va ti on [5], 
substrate specifi city [6, TJ, and reacti on m echanisms [8,91 of such 
enzymes . O nce the secreted fo rm of this enzy m e, proco ll agenase 
[10, 11], has been acti va ted in the ex tracellul ar space, a m aj o r 
m odifi er of coll agenase acti v ity appea rs to res ide in th e 28,500 
dalton co llagenase inhibitor also produ ced by derm al fibro blasts 
[1 2). T hi s glycop ro tein has been purifi ed (1 3), biochemi ca ll y char-
acterized [1 3], its co mplete primary stru cture determin ed by bo th 
amin o acid [1 4] and cDNA nucleotide seguence [14,15], and has 
been shown to fo rm very hig h affinit y (Ki - 10- 10 M ) co mplexes 
w ith coll agenase [1 6, 17). Its inhibito ry spectrum also includes 
o ther m etallo pro tein ases of co nn ective tissue o ri gin such as gel-
atinase an d proteogl ycanase [13,18J. Imll1unologica ll y and fUll c-
tionall y identica l coll agenase inhibito rs have been identified in cell 
cultures of hul11 an lun g, ging iva l, and corn ea l fi bro bl as ts, ute rin e 
smooth muscle cel ls, and tendon and cartilage explants [19J. Very 
recentl y, this glycoprotein has also been fo und in the a - g ranul e 
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blister fluid was studied usin g hea t- and suction-indu ced 
bullae. T he concentration in newly formed blisters was 
- 0.5 ,ug/ml , virtu all y identi cal to plasma inhibitor levels, 
and remained constant for approximatel y 4 h. Inhibitor 
concentrations then rose rapidly , reaching pea k values of 
- 6 Jig/ml after 48 h. We speculate that the role o f this 
inhibitor in blister fluid involves the inhibitions of active 
proteinases w ithin the bulla cavity and m ay occur to limit 
the extent o fbJi ster fo rmation or to assist in wo und repair. 
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of hum an pla te lets [20] and as a secreto ry produ ct of human 
m ononuclea r phagocytes [21,22]. Interes tin gly, the sa m e inhibitor 
m o lecule apparentl y ga ins access into cer tain bod y Auids such as 
pl as m a and amniotic Auid [1 9]. Indeed , the ubiguity o f this in-
hibitor protein and its ca pacity to m o dulate th e ac ti vity of multiple 
enzy mes suggest th at it m ay occupy a crucial positi on in con-
trolling the turn over of coll agen in m any connecti ve tissues of 
th e bo d y. 
T he ro le of pro teinases in the path ogenesis of blisterin g dis-
o rders is not adequ atel y un ders tood. Eleva ted levels o f co Llagenase 
[23,24) and elas tase [24] have been documented in a va riety of 
inA ammatory blister Auids. While th e actio n of th ese enzym es is 
no t generaUy believed to represent th e principal underl yin g etiol-
ogy of such diseases, protein ases m ay fun ction as fin al, common 
m ediators o f bull a fo rm ati on . H owever, in o ne particular dis-
order, the recessive dystrophic fo rm of epiderm o lys is bullosa, 
evidence has been accumulated to suggest a pathogeni c role in-
vo lvi ng the synthesis of increased q uantities of a ca taly ticall y 
no rm al, but structurall y aberran t co llagenase [25-28). Further-
m o re, M anabe et al [29] have shown that blister Auids fro m dom-
in ant epiderm o lysis bullosa sim plex o r fro m recess ive d ys troph ic 
epiderm olysis bullosa, when incubated with no rm al cul tured skin 
explants, ca n induce th e blister fo rm atio n typi ca l fo r each re-
spective disease. In the present report, we have determined that 
large am ounts of hum an coll agenase inhibito r arc also present in 
inA amm atory bli ster fluid s' of diverse cau sati on . Quantitation of 
sLl ch levels by enzy me-linked ill1ll1unoso rbent assay (ELI SA) re-
vea led that inhibi to r was accumul ated w ithin bull ae to concen-
trati ons so me 4- to 20-fold greater than fo und in pl as m a. 
MATERIALS AND METH ODS 
Materials Po lys tyrene m icro titrati on pla tes (Mi C-2000 fo r col-
lagenase inhibi to r E LISA, Immulon-2 fo r collagenase E LISA) were 
pu rchased fro m D ynatech. Goat antirabbit IgG conjuga ted to 
alkaline phosphatase and p-nitrophenyl phosphate (disod ium) were 
ob ta ined from Sig m a. A bsorbance readings of th e solutions in 
the microtitratio n pl ates we re m easured at 405 nm w ith an au-
to m ated Flow T itertek colo rimeter. 
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Patient Selection, Blister Decolnpression, and Venipunc-
ture Bliste r fluid and serum sa mpl es were obtained from patients 
w ith bullous diso rders who represented both inpatients and out-
patients from va rious hospita ls at the Washington University 
Medical Center, St. Louis, Missouri , and th e Veterans Admin-
is tration H osp ital, M emphis, Tennessee. In m ost patients (14 /20 
in T able I and all 18 in Table lll ), a 3-mm skin punch biopsy was 
perform ed at th e tim e of bli ster decompress ion or had been ob-
ta ined previously when the patient 's diagnosis was established. 
In the remainin g 6 patients (nos. 1, 2, 3, 7, 8, and 19 in Table I), 
the diagnosis w as readil y apparent o n clini cal g rounds alone. The 
histolog ic and clinical findin gs were in complete agreem ent for 
all patients included in the stud y. B lister fluid was obtai ned from 
each patient by asp iration of a sin g le bullous lesion usin g a 20-
ga u ge needle and sy rin ge after preparation w ith 70% alco hol. A 
minimum vo lume of 25-50 ILl was collected for each ELISA 
determination. In each case the blisters were at least 24 h o ld . At 
the sa m e patient vi sit durin g w hi ch blister fluid was obta ined, a 
10-111.1 venipuncture sa mpl e was coll ected and allowed to clot fo r 
several ho urs. After removal of the clo t, th e serum was clarified 
by centrifu ga tion at 2000 g for 20 min. Seru m a l~d blister fluid 
specimens were stored at - 20°C. All specimens were obtained 
prior to th e initiatio n of m edi cal therap y o r during an exacerbation 
of disease precipitated by th e patient hav in g discontinu ed o ral 
medi ca tion s aga inst advi ce. 
Suction Blisters Blisters were induced on th e ventral surfaces 
of the forearm s of o ne of the au thors usin g a co m binati on of heat 
and vacuum applied for approx imately 20 min. A total of7 blis-
ters, each 8-] 0 mIll in diameter were produced w ith in a 2-h period 
an d were aspirated at tim e intervals ran g in g from 2- 96 h. 
Assay Procedures Collagenase inhibitor levels in serum and 
blister fluid specimens were quantitated immunologicall y by ELISA 
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as described previo usly 11 9]. Coll agenase in the sa me blister fluid 
sa mples was also m eas ured by ELISA as reported by Cooper et 
al [30]. It sho uld be emph as ized that each assay meas ures the tota l 
amount of th at parti cular pro tein present, w hether it exists in a 
bound or free state [1 7,19). 
Doubl e immunodiffusio n was perform ed usin g 1.0% Ionagar 
as previously described by O uchterlo ny [31] . T he gel was pho-
tograhed followin g o vernig ht dialysis aga inst 0.05 M Tris-HCl, 
pH 7.5, containing 0.15 M N aCI and a brief 4-h wash in distilled 
wa ter. 
RES ULTS 
Samples of blister fluid and o f serum were obta ined simulta-
neously from pati ents w ith a va riety of bullous disorders. The 
collagenase inhibitor concentration of the specimens was deter-
mined b y ELISA , and th e results are shown in T able I. Sera from 
the 20 individuals examined contained an average of 1. 39 ILg/ ml 
of immuno reactive coll age ll ase inhibitor, with a stand ard error 
of 0.09 ILg/ ml and a sta ndard deviation of approx imately 30% 
arou nd the mean. Both the mea n inhibi tor concenrration and the 
range o f va lues w ere similar to those observed in the sera o f 
patients w ho w ere hospitalized on the derm atology service fo r 
treatment of non bullous diseases (Table II) and in a group of 
clini ca ll y 11 0 rmal individuals repo rted prev iously [1 91· 
As co mpared w ith se rum va lues , levels of collagenase inhibitor 
present in blister fluid s w ere generally of much hig her ma gnitude 
and also exhibited g rea ter va riation (Table I). Thus, in 17 of the 
20 patients evaluated in this study, blister fluid inhibitor levels 
exceeded those present in serum, and in 22 of the 26 samples 
exam.ined , thi s difference was greater th an 2-fold . 011 the average, 
blister Auids contained 3- to 4-fold g rea ter concentratio ns of co l-
lagenase inhibitor than co rres ponding sera , but differences in ex-
Table I. Collagenase Inhibi tor Concentration in Various D erm atoses 
Blister Fluid (J.Lg/ ml ) Serum 
Patient Inhibitor 
No. Clinical Disorder A gc/ lbce/Sex Inhibitor Coll agenase (J.L g/ ml ) BF/ S" 
Acute contact derm atitis 51/ B/ M 3.42 1.78 1.J 2 3. 1 
2 Acute contact dermatitis 28/W/ F 2.83 0.65 1.1 8 2.4 
3 Dyshid rotic cczema 23/B / F 5.50 0.14 1.84 3.0 
6.52 3.5 
4 Erythcma multi fo rm e/TENb 28/W/ F 2.90 0.25 1. 00 2.9 
5 Bullous erythema multiforme 77 /W/ F 12.54 0.25 1.78 7.0 
6 Bullous dru g cruption 551BI M 4.84 ND' 1.42 3.4 
7 Phototo xic reaction (UVB) 78 /W/ F 10.23 ND 1.10 9.3 
10.24 9.3 
10.20 9.3 
8 Acute radiation derm atitis 80/W/ F 3.25 2.36 0.95 3.4 
9 Pcmphigus vulgaris 43/B / F 2.62 ND 0.87 3.0 
10 Pemphigus vulgaris 22/B / M 7.47 ND 0.84 8.9 
II Pemphigus vulga ris 68/ W/ M 4.70 0.00 1. 60 2.9 
12 Bullous pemphigoid 65/W / M 5.22 0. 11 1. 71 3.1 
6.09 1. 82 3.6 
6.66 0.65 3.9 
13 Bullous pemphigoid 79 / W/ F 2.85 0.1 4 1.32 2.2 
14 Bu llous pemphigoid 86/B / M 3.37 ND 
15 Bu llous pemphigoid 78 /B /M 1. 84 0. 15 
1. 54 2.2 
1. 80 1.0 
3.56 2.0 
16 Acq uired EB - / W/ M'/ I. 55 ND 2.00 0.8 
17 Linear IgA derma tos is 58/W/ F 3.24 0.85 1. 05 3. 1 
18 Bullous diabetico rum 55/W / M 1. 20 0. 13 1. 34 0.9 
19 Pressure blister 62/W /F 2.65 0. 15 1. 26 2. 1 
20 Coma blister 78 /W/M 0.92 0.50 2.06 0.5 
Mean ± SE 4.86 ± 0.6J'· 0.68 ± 0. 18 1.39 ± 0.09 3.7 ± 0.5 
"' Ratio of blister fluid / serulll illhibitor cOll ccntrario ns. 
"TEN , tox ic epiderlll al Il ccrolys is. 
rND, assay not don!.!. 
JA gc unknown. 
'p < 0.000 1 compared with serlllll collcclltratiol1. 





















Table II. Serum Inhibi to r Concentrati o ns in 
Vario us D erm atoses 
Serum Inhibito r 
Concentration 
Clinical Disorde r Agc/Racc/Sex (ILg/ml ) 
Psorias is 52/W/ F 1.1 7 
Cellu litis 84/W/F 1.2 1 
Basa l ccll ca rcinoma 78/W/ F 1. 17 
Psori as is 60lB / F 1.43 
Psori as is 50lB/F 1.40 
Psori as is 28/W/F 0.72 
Eczcma 40/W / M 0.76 
Eczc ma 44/B/F 1. 10 
Mycosis fun goidcs 86/W/M 1.1 4 
Eczc ma 55/W/ M 1.05 
Eczema 63/W/ M 1.34 
Mycosis fungoidcs 75/W/F 1. 24 
Mycosis fungoides 53/W/ M 2.07 
Psori as is 27/W/ F 1. 21 
Psori as is 39/0/M 1.47 
Psori as is 25/W /F 1.75 
Psori as is 28/W/F 1. 96 
Psori as is 47/W/ F 1.43 
Mean ± SE 1.31 ± 0.08 
cess of7-fo ld ~ere o bscrved in 3 paticn ts. In o n ly 3 indi vidu als-
1 w ith acq u ired epid erm olys is bu llosa (no. 16), 1 w ith bu llo us 
diabeticorum (no . 18) , and 1 w ith a co m a-induced blister (no . 
20)-did serum inhibito r m easu re m cnts exceed va lues determin ed 
in the blister fluid s. 
It sho uld also be no tcd th at coll agenase inhibi to r co ncen tratio ns 
present in serum are approx im ately 2-fo ld g rea ter th an th ose o f 
plasm a, the di fference bein g accounted fo r by release of this pro-
tem fro m platele t a-g ranu les durin g the cl o ttin g process [20] . 
T herefo re, w hil e blister fluid s contained 3- to 4-fo ld g rea ter m ea n 
conccntratio ns of collagcnasc inhi b ito r than were fo und in thc 
sa m e indi v idu al's serum , such d ifferences were even larger , 6- to 
8- fo ld , w hcn co mpared w ith a m o re appro pri atc extracell u lar 
fluid , plas m a. Levels of coll agenase inhibi to r in bu ll ae also ex-
hibited m o re va riabi lity than did th ose present in se rum ; a s tan-
dard erro r of 0.61 JLg/ ml and a standard dev iatio n of 66% wcre 
o bserved fo r the b lister fl u id sa mples as co m pared w ith va lues o f 
0.09 JLg/ ml and 30%, respecti vel y, fo r the co rrcspondin g sera . 
In several paticnts, it w as possibl e to o btain bli stcr fluid specim ens 
fro m m o re than 1 bu ll o us les io n. Analysis o f inhibito r levels in 
such sa mp les fro m th e sa m c patient rcvca led that, by and large, 
such d ifferences we re relatively min o r in degree (nos . 3, 7, 12, 
and 15), and th at mu ltiple blister fluid s fro m tbe sa m e indi vidu al 
gcnera ll y contain ed simil ar am o un ts of coll agenasc inhibito r. 
In o rder to ga in insight in to th e pathogcni c m echanism s fo r 
th e eleva tcd coll agenase inhibito r levels p resent in blis ter fluid s 
of divcrse eti o logy, ex perim cn ts wcre perfo rm ed utilizin g hea t-
and suctio n- induced bu ll ae as a m odel systcm . A series o f such 
blisters was in d uced o n the vcntral surfaccs of o ne autho r' s fo rc-
arm s and fluid evacuated at va rio us tim e intcrva ls ran g in g fro m 
immediatel y fo ll owin g bu ll a fo rm atio n to 96 h afterwa rds. The 
b lis ter fluid s were thcn subj ected to E LI SA and the rcsultant data 
rel atin g inhibito r concentratio n to tim e elapscd after blis ter in-
du cti on arc shown in Fig 1. The coll agenasc inhibi to r content o f 
a newly fo rmcd b lister was 0.50 JLg/ml , virtuall y identi ca l to th is 
indi vidual's p las m a inhibito r concentrati o n (0.53 JLg/ Il1I). This 
lcvcl of inhibito r protein rc m aincd constant fo r approx imatel y 4 
h, a ft~ r w hIch tim e inhibito r conccntrati o n bega n to ri se rapid ly, 
rcachlll g a pcak va luc o f 6 JLg/ ml after 48 h . T hu s, the evo lutio n 
o f a suctio n- indu ced bl ister was charac terized by initi al coll agen-
ase lllhlbIto r levels v irtu all y id enti ca l to th ose present in p lasma , 
fo ll owed by a rapid 10-fo ld ri se in this pro tein' s concentratio n 
w ithin th e blister cav ity o ver the next 2 days. 
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Figure 1. Time course of co ll agcnase inhibitor levels in suction-induced 
bu ll ae. A se ries of 7 heat- and suction-induced blisters were induced on 
the ventral surfaces of one author's forea rm s. At va rious time intervals 
rangin g fro m immediately fo llow in g blister form ation (time = 0) to 96 
h afte rwards, Auid was evacuated (onl y once per blister) and collagenase 
inhibitor concentration determined by E LI SA. The dOlled lill c represents 
the correspondin g plasma concentration of inhibi to r. 
A lth o ug h the specifi city of the E LI SA fo r co llagenase inhibito r 
has been docum ented prcvio usly [1 9,21,22], do ublc-immuno-
diffusio n studies were perform cd to ga in insig ht into the extent 
of immun o logic similarity between th e antigen m easured in blis-
te r fluid s and th e co lbgenase inhibito r produced by human skin 
fibro blasts. As show n in Fi g 2, a precipitin line o f id entity de-
velo ped between concentrated b lister fluid and pure fibroblast 
inhibi to r w hen sa mples o f bo th w ere reacted in gel diffusion 
again st antibod y to th e fib ro b last pro tein. There fo re, b lis ter fluid 
does ind eed contain an anti gen w hich is immu no logicall y identical 
to th e ski n fibro bla st inhibito r. 
Suffi cient am o unts o f b lister flu id were o btaincd fro m the bullae 
o f m os t patients in this s tud y to also determ in e collagenase con-
centrati o ns b y E LI SA [30]. Interes tin gly, as shown in T able I, 
th ere w as no o bv io us co rrelation between en zym e and inhibi tor 
levels; ho w ever , the inhibito ry pro tein w as in va riably present in 
a h ig her co ncentration th an co llagenase. The degradatio n of col-
lagenase by o ther b lis ter fluid pro tein ases co ul d conceivably ex-
pl ain these results. Alternatively, the data at leas t sugges t the 
Figure 2. Immunologic co mparison of blistcr Auid vs human skin fi-
broblast co llagenase inhibitor. Concentrated bliste;' Auid (2.5-fold) from 
patient 7 was reacted in gel diffusion with pure fibroblast co llagcnase 
IIlh ,bltor 1131. Antibody to the fibroblast protein is conta incd in the center 
well. 13, Blister flu id; F, pure fibroblast co llagenase inhibitor. 
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possibility th at in fully developed blisters sufficient quantities of 
inhibitor are present to block the enzy mati c activity of coll agenase 
as welJ as other· conn ective tissue metall o proteinases affec ted b y 
this inhibi to r. 
In this rega rd . we determined inhibitor concentratio ns in blister 
fluids from patients w ith va rious types of ep iderm olys is bu llosa, 
since it is possible th at certain proteases m ay playa role in the 
tiss u e destruction that acco mpanies bulla formation [23-28J. As 
shown in Table Ill, w hi ch rep resents 26 blister fluid sa mpl es 
obta ined fro m 18 separate patients , blister fluid inhibi tor concen-
tra tions were a m ea n 2.5- to 3.7-fo ld increased over serum va lues 
in a ll fo rms of epiderm o lys is bullosa. Although the data showed 
a tendency to hig her inhibito r levels in blister fluid s from the 
clini cally more severe recess ive dystrop hic and recess ive junc-
tional fo rms of the disease (Table III ), the range of values was 
within th at o bserved for other blistering dermatoses (Ta ble I) and 
the increases were not stati sti ca ll y signifi cant. It is also notewo rth y 
that in recessive dystrophi c epiderm olysis bullosa, a disorder in 
part characterized by excessive synthesis of co llagenase [23,25-28], 
there were entirely norm al serUIll levels of the coll agenase inhib-
itor, suggest in g that the tissue evidence of collagenolysis is not 
the result of deficient circul at in g inhibito r. 
D ISC U SSIO N 
T h e results of this stud y clearly indicate that a protein immu-
nologica ll y iden ti ca l to th e collagenase inhibitor produced by hu-
man skin fibro blasts is fo und in hi gh concentrations in bullae o f 
dive rse etio logies . Levels of collagenase inhibito r in blister fluid s 
ranged from 0.9-1 2.5 /-Lg/m l, averagin g 4.9 /-Lg/m l. The mea n 
values were 3- to 4-fold g rea ter than those presen t in sera and 
exceeded plasma levels by 6- to 8-fold. By double-immuno-
diffu sion analys is, this protein appea rs to be immunologically 
identica l to th e co llagenase inhibitor secreted by hum an sk in fi-
broblas ts which inhibits collagenase activity via the formation of 
a very hi gh affi nity enzy m e-inhibitor co mplex [17] . Wh ile the 
exact nature o f the role ofprotein ases in the pathogenesis of bullae 
in a number of different bli stering disorders has remain ed un-
defU1 ed, th eir presence in blister fluids is well established (24). 
More importantl y, ava il able evidence fro m usin g blister fluids 
from 2 types of epidermo lys is bullosa sugges ts that their proteo-
lytic activity mediates actual blister formation in vitro in no rmal 
human sk in target tiss ues [29]. Our report now presents the first 
evidence that a specifi c proteinase inhibitor is also a maj o r 
con s tituent of blister fluid and is present in sufficientl y hig h con-
centrations to inhibit at least so me of the activity of m etallopro-
teinases contained w ithin these bullae. Whether this occurs-
teleologica ll y-to prevent excess ive tissue destruction o r, alter-
natively, represents a scavenger function of the inhibitor cann ot 
be resolved by o ur data. 
The eleva ted levels of coll agenase inhibi to r found in blister 
fluids of multiple ca usation suggest that derma l fibroblasts are th e 
likely source of this protein. Although plasma [20] and serum 
[19,20] also contain immunologicall y and functionally identi ca l 
molecules to skin fibrob las t inhibitor, the levels were virtua ll y 
Table III. Serum and Blister Fluid Inhi bitor Concentrations 
in E piderm ol ys is Bullosa 
Type of Epiderm olys is 
Bullosa (EB) 
Inhibi to r Concentration 
(J.tg/ l11l ) 
Dominant EB simplex 
Dominant dystrophic EB 
Recess ive junctional EB 







1.05 ± 0.08 
NO' 
NO 
1. 65 ± 0.28 
aN umbcr of p:Jticl1ts exam in ed ill each group. 
bp < 0.000 1 co mpared with se rulll concentration. 
'N D, assay not dO lle. 
dp < 0.005 compared with se rUIlI concentration. 
Blister Fluid 
2.6 1 ± 0.271> 
2.82 ± 0.52 
4. 12 
3.72 ± 0.36.1 
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iden tica l in bullous disease patients, in a group of dermatology 
inpatients hos pitali zed for treatment of non bu llo us derm atoses 
(Table II ), and in normal hea lthy volunteers [1 9]. Additionall y, 
serum levels were on ly 25- 30% of bli ster fluid inhibitor concen-
tJ·ations, w hile th ose present in plas m a were less than 15%. Fur-
thermore, the time course of inhibi tor accumulation in heat- and 
suction-ind uced blisters also supports the concept of a fibroblasti c 
source of this protein. At the time of blister formation and for 4 
h afterwa rds, levels of collagenase inhibito r approximated those 
present in plasma. Between 4-12 h, however, inhibito r concen-
trations rose abruptl y, reachin g m axim al levels by 48 h w hich 
were 10- fo ld greater th an plasma concentrati ons. Thus, wh ile 
plasm a is probably the source of collagenase inhibi tor initiall y 
present in blister fluid , it is unlikely to be responsible for the 
accumu lati on of such m aterial within the cavity. 
Althou gh the data in this stud y do not add ress the m echanisms 
of collagenase inhibitor accumulation w ithin bullae, so m e spec-
ul ation into this matter is ap propriate. Inflammatory cell s are 
unlikely to serve as a direct source since neutrophils [1 3,20] and 
lymphocytes [20] do not contain this protein; collagenase inhibitor 
is secreted by m acro phages 121,22] and plate lets [20), bur the 
former are not found in significant quantity durin g the acute 
inflammatory process, w hile continued platelet degranulation would 
no t be expected to occur 4-48 h after the ini tial traum ati c event. 
A m ore attractive hypo th esis wo uld in volve the stimulatio n of 
collagenase inhibito r synthesis by derm al fibrobla sts , perhaps in 
response to a soluble med iator elabora ted during th e inflamma-
tory process. In this regard, the m onocyte/macrophage product 
interl eukin 1 has been shown to stimulate the release of both 
coll agenase [32] and co llagenase inhibitor [331 by hum an fibro-
bl as ts. Similarl y, a solu ble med iato r derived from epidermal cell 
cultures, w hich m ay be related to interleukin 1, also aug m ents 
th e production of both proteins by dermal fibroblasts [34] . Per-
haps cytokines released from resident damaged epiderm al cells or 
by mig rat in g inAamll1ato ry cells, or even g rowth facto rs w ith 
properties simil ar to those of the tum or pro m oter, phorbol my-
ristate acetate, another substa nce known to en hance the biosyn-
thesis of both coll agenase and inhibito r [33,35], are responsible 
for stimulating fibroblast production of collagenase inhibito r w hich 
then becomes sequestered in blister fluid . 
The biologic role of the collagenase inhibitor in blister fluid 
presumabl y relates to a function in vo lvin g the inhibition of active 
proteinases w ithin the bull a cavity . Although one such proteinase, 
interstitial co llagenase, is discussed in this repo rt, a number of 
other m etall oprotein ases m ay be present in blister fluid . T hese 
enzy mes m ay be of g rea t significance in the degradation of non-
inters titi al coll agens (i.e., type IV o r V) as well as proteoglycans, 
elas tin , and other elements of the extracellular m atrix and , im-
portantl y, the basem ent m embrane zone. Human sk in coll agenase 
inhibitor blocks the activ ity of a number of these proteinases 
[1 7, 18]; thus , it m ay playa crucial role in the processes of both 
epider mal and derma l wound hea lin g. Indeed, the almost uni fo rm 
presence of elevated collagenase inhibitor levels in bull ae of mul-
tip le causation and the tim e course of the inhibitor 's appearance 
in suction blisters mi ght argue that the presence of this protein 
in such fluid s may be a common response to injury and m ay occur 
to limit the extent of bull a formation or to ass ist in wound repair. 
Furthermore, it may be that the temporal nature of the influ x of 
proteinases and inhibitors in to the blister cavity is critical; thus, 
adequate levels of coll agenase inhibito r m ay occu r only afte r sig-
nifi cant damage has already taken pl ace. In an y event, the d ata 
presented here suggest the possibility that m easurement of bli ster 
fluid collagenase inhibito r levels may be useful in m on ito ring the 
activity of certa in bullous dermatoses o r even that the ad minis-
tration of such an agent m ay be clinically useful in suppressing 
the blisterin g process . 
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